COMPUGEN LTD
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 5.2
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | Before market open | $2.60M | $-0.07 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 2, 2026 | Before market open | $67.30M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $1.30M | $-0.08 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | Before market open | $1.50M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $6.70M | $-0.02 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | Before market open | $33.50M | $0.11 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 7, 2023 | Before market open | – | $-0.11 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 27, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 4, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Feb 24, 2022 | Before market open | – | – | – |
Press releases
Announcements Compugen filed with the SEC
You are cordially invited to attend, and notice
EX-99.1 to Form 6-K
Reports Second Quarter 2026 Results
EX-99.1 to Form 6-K
Represents an amount lower than $1
EX-99.2 to Form 6-K
AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION
EX-99.3 to Form 6-K
COM701 MAIA-ovarian trial actively enrolling patients across all clinical
EX-99.1 to Form 6-K
Compugen Reports Fourth Quarter and Full Year 2025 Results
EX-99.1 to Form 6-K
Compugen Announces the Appointment of Michele Holcomb, Ph.D.,
EX-99.1 to Form 6-K
Compugen Monetizes Portion of Rilvegostomig Future Royalties
EX-99.1 to Form 6-K
Compugen Reports Third Quarter 2025 Results
EX-99.1 to Form 6-K
Compugen to Present Pooled Analysis of COM701 in Three
EX-99.1 to Form 6-K
Compugen Reports Second Quarter 2025 Results
EX-99.1 to Form 6-K
Represents an amount lower than $1
EX-99.2 to Form 6-K
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
EX-99.3 to Form 6-K
Compugen Announces First Patient Dosed in COM701 Global
EX-99.1 to Form 6-K
Compugen Reports First Quarter 2025 Results
EX-99.1 to Form 6-K
Compugen Announces Leadership Transitions Effective September 2025
EX-99.1 to Form 6-K
Compugen Reports Fourth Quarter and Full Year 2024 Results
EX-99.1 to Form 6-K
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to
EX-99.1 to Form 6-K
Compugen Expands its Intellectual Property Portfolio with
EX-99.1 to Form 6-K
Compugen Reports Third Quarter 2024 Results
EX-99.1 to Form 6-K
Activity and Safety Data of COM701, COM902 and
EX-99.1 to Form 6-K
Compugen Reports Second Quarter 2024 Results
EX-99.1 to Form 6-K
Represents an amount lower than $ 1.
EX-99.2 to Form 6-K
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
EX-99.3 to Form 6-K
Compugen Announces FDA Clearance of IND for COM503
EX-99.1 to Form 6-K
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient
EX-99.1 to Form 6-K
Compugen Reports First Quarter 2024 Results
EX-99.1 to Form 6-K
Compugen Appoints David Silberman as
EX-99.1 to Form 6-K
Compugen Reports Fourth Quarter and Full Year 2023 Results
EX-99.1 to Form 6-K
Michelle Mahler M.D. as Chief Medical Officer
EX-99.1 to Form 6-K
Regains Compliance with Nasdaq Minimum Bid
EX-99.1 to Form 6-K
Compugen to Receive $10 Million Milestone Payment Following
EX-99.2 to Form 6-K
Yvonne Naughton, Ph.D., Investors and Media
EX-99.1 to Form 6-K
Compugen will be Eligible to Receive $10 Million Milestone
EX-99.2 to Form 6-K
Compugen Reports Third Quarter 2023 Results
EX-99.1 to Form 6-K
Compugen’s COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in
EX-99.1 to Form 6-K
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
EX-99.1 to Form 6-K